In the NSCLC cell line HCC78 with the SLC34A2-ROS1 rearrangement, three ROS1 mutations causing drug resistance, G2032R, L2026M and S1986Y, were knocked down using CRISPR/Cas9 technology. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.